AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer ' s Disease and Progressive Supranuclear Palsy

NORTH CHICAGO, Ill., Jan. 25, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced the start of two Phase 2 clinical trial programs to evaluate ABBV-8E12, an investigational anti-tau antibody, in patients with...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials